- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Multiple Endocrine Neoplasia Type 2B
Total 58626 results
-
Isfahan University of Medical SciencesCompletedSecondary Progressive Multiple SclerosisIran, Islamic Republic of
-
BiogenTerminatedSecondary Progressive Multiple SclerosisUnited States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
-
Eli Lilly and CompanyBioMS Technology Corp.TerminatedSecondary Progressive Multiple SclerosisCanada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
-
Eli Lilly and CompanyBioMS Technology Corp.CompletedSecondary Progressive Multiple SclerosisCanada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
-
Wyeth is now a wholly owned subsidiary of PfizerTerminatedSecondary Progressive Multiple SclerosisGermany
-
Fundacion Clinic per a la Recerca BiomédicaRecruitingIntraductal Papillary Mucinous Neoplasm of PancreasSpain
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
-
AbbVieTerminatedExocrine Pancreatic Insufficiency (EPI)United States
-
Archemix Corp.CompletedPurpura, Thrombotic Thrombocytopenic | Von Willebrand Disease Type-2bAustria
-
Tehran University of Medical SciencesCompletedMultiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple SclerosisIran, Islamic Republic of
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)TerminatedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Innate ImmunotherapeuticsSyneos HealthCompletedSecondary Progressive Multiple SclerosisNew Zealand, Australia
-
BiogenTerminatedMultiple Sclerosis, Secondary ProgressiveUnited States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
-
BiogenWithdrawn
-
University College London HospitalsCompletedSecondary Progressive Multiple SclerosisUnited Kingdom
-
University Hospital, MontpellierTerminatedType 1 Diabetes | Basal-bolus Multiple-dily Insulin Injections | Insulin Pump (CSII)France
-
Memorial Sloan Kettering Cancer CenterHealthTree FoundationRecruitingMultiple Myeloma, SmolderingUnited States
-
Regeneron PharmaceuticalsRecruiting
-
Omar Nadeem, MDJanssen, LPRecruitingMultiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Icahn School of Medicine at Mount SinaiPharmacyclics LLC.TerminatedHigh Risk Smoldering Multiple MyelomaUnited States
-
University of ArkansasMillennium Pharmaceuticals, Inc.CompletedAsymptomatic Multiple MyelomaUnited States
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
Masonic Cancer Center, University of MinnesotaTerminatedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Germ Cell TumorUnited States
-
Kyverna TherapeuticsNot yet recruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
-
University of UtahCompletedMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsActive, not recruitingActive Secondary Progressive Multiple SclerosisItaly
-
Novartis PharmaceuticalsTerminatedSecondary Progressive Multiple Sclerosis With Inflammatory Disease ActivitySwitzerland
-
Medical College and Hospital KolkataSir Ganga Ram HospitalCompletedPancreatic Endocrine Neoplasms
-
Fondazione Policlinico Universitario Campus Bio-MedicoCompleted
-
University of FloridaCompleted
-
Shanghai Zhongshan HospitalUnknownCarcinoma, Pancreatic Ductal | Circulating Tumor CellsChina
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States
-
National Cancer Institute (NCI)RecruitingPlasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Peng LiuShanghai East Hospital; Hrain BiotechnologyUnknownMultiple Myeloma in Relapse | Multiple Myeloma ProgressionChina
-
US Oncology ResearchKaryopharm Therapeutics IncRecruitingMultiple Myeloma | Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Kahler Disease | Myeloma, Plasma Cell | MyelomatosisUnited States
-
University of Illinois at ChicagoCompletedMultiple Myeloma, Relapsed | Multiple Myeloma, Refractory to Standard TreatmentUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden